Rare Disease Report

Is rIX-FP a Game Changer for Hemophilia B?

DECEMBER 08, 2015
Elena Santagostino, MD, PhD



Elena Santagostino, MD, PhD, of entro Emofilia e Trombosi, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico in Milan, Italy discusses the safety and efficacy of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in two phase 3 studies involving hemophilia B patients. As Dr Santagostino states in the interview, this may result in a paradigm shift in how these patients are managed.

Reference

Santagostino E, Voigt C,  Wolko D,  Cole G, Yanyan Li Y,  Jacobs IC. Efficacy and Safety Results of Prolong-9FP Clinical Program of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B.  Poster presented at 57th ASH Annual Meeting; Orlando, Florida; December 4-8, 2015. Abstract 548.

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.